S&P 500 Marks Second Losing Week in 13 as AI Wreck Overwhelms Broad Market Gains
Key Takeaways
- Despite nearly 66% of S&P 500 stocks climbing, the index posted its second losing week in 13 as heavy selling in AI megacaps like Micron completely negated the broad market rally.
- Oil prices dropped to pre-Iran crisis levels, boosting transportation and healthcare stocks, while Eli Lilly soared 7.1% on European drug approvals.
Mentioned
Key Intelligence
Key Facts
- 1The S&P 500 slipped less than 0.1% on June 26, 2026, marking only its second losing week in the last 13 weeks.
- 2Brent crude oil fell 3.8% to $72.60 per barrel, returning to its price level before the U.S.-Israel attack on Iran and the closure of the Strait of Hormuz.
- 3Eli Lilly's (LLY) shares surged 7.1% after a European Medicines Agency committee recommended approvals of several drugs, driving health care stocks higher.
- 4Micron Technology (MU) tumbled 6.7%, the heaviest weight on the market, despite its stock having roughly quadrupled earlier in the year due to AI-driven demand for memory chips.
- 5Nearly two-thirds of all S&P 500 stocks advanced on the day, but declines in AI megacaps overwhelmed the broad market rally.
- 6The Dow Jones Industrial Average fell 44 points (0.1%), and the Nasdaq Composite lost 0.2%, both weighed down by the AI sector.
Who's Affected
European Medicines Agency committee recommended drug approvals
Analysis
For portfolio managers and market strategists, June 26’s action was a textbook illustration of concentration risk: a powerful internal rotation that would have lifted a flat-weighted index ended up delivering a loss because AI giants now dominate cap-weighted benchmarks. With AI-related names exerting outsized influence on the S&P 500 and Nasdaq, sector-specific volatility can dictate overall market direction.
The U.S. stock market delivered a starkly mixed session on June 26, 2026, as a broad advance across the majority of shares was completely overshadowed by a deepening sell-off in artificial-intelligence stocks. The S&P 500 slipped less than 0.1%, the Dow Jones Industrial Average dipped 44 points (0.1%), and the Nasdaq composite fell 0.2%. This left the market recording only its second losing week in the last 13, a notable interruption in an otherwise powerful rally that had been fueled by AI fervor and hopes for economic resilience. The day's action underscored two competing forces: relief from geopolitically driven energy costs and growing anxiety about the sustainability of AI valuations.
The S&P 500 slipped less than 0.1%, the Dow Jones Industrial Average dipped 44 points (0.1%), and the Nasdaq composite fell 0.2%.
The easing of oil prices was a major tailwind for broad market sectors. Brent crude, the international benchmark, dropped 3.8% to settle at $72.60 per barrel, a level that fully unwound the spike triggered by the U.S. and Israel’s attack on Iran, which had led to the closure of the Strait of Hormuz and a severe curtailment of global oil shipments. Energy-intensive industries immediately benefited; American Airlines Group climbed 1.7% as fuel cost expectations improved. Health care stocks also surged after a committee of the European Medicines Agency recommended several medicines for approval and for extension of therapeutic indications, including one for Eli Lilly, sending Lilly’s shares up 7.1%. This pharmaceutical boost, combined with lower fuel costs, lifted nearly two out of every three stocks within the S&P 500. By traditional breadth measures, it should have been a strong up day.
What to Watch
However, the gravitational pull of AI stocks was simply too powerful to resist. After leading the market to extreme heights for years, these shares have entered a treacherous phase defined by doubts over whether profits can ever catch up with their stock price rallies. Because AI companies have ballooned into the largest and most influential components of market-cap-weighted indexes, small moves in their share prices have an outsized impact on headline numbers. Micron Technology was the heaviest weight on the market, its stock plummeting 6.7% in a single session. The memory-chip maker has been a prime beneficiary of the AI boom, seeing its stock roughly quadruple this year on insatiable demand for high-bandwidth memory required by AI accelerators. Yet, on this day, investors brutally repriced the risk that such momentum might not be permanent. Other AI-inflated names also suffered, dragging the entire Nasdaq into negative territory.
The juxtaposition of broad market strength and concentrated AI weakness highlights a market increasingly vulnerable to a valuation reset in the very sector that has powered its gains. With the S&P 500’s concentration at extreme levels, systematic selling in AI names can mask improvements in the rest of the economy. The oil price normalization, if sustained, could relieve pressure on inflation and consumer spending, potentially benefiting the vast majority of non-AI companies. Meanwhile, the European drug approvals offer a reminder that innovation and cash flows exist beyond the technology sector. Yet, for the immediate future, the trajectory of major indexes will be dictated by whether AI companies can deliver earnings that justify their still elevated multiples, or whether the recent selling pressure foreshadows a broader rotation out of high-beta tech names. The market’s failure to rally on a day when most stocks rose is a warning that, in a cap-weighted world, concentration risk is now the dominant market variable.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |